[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 93 of about 93
1. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


2. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD: Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer; 2008 Nov 15;113(10 Suppl):2892-900
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the burden of human papillomavirus-associated anal cancers in the US.
  • BACKGROUND: Anal cancer is an uncommon malignancy in the US; up to 93% of anal cancers are associated with human papillomavirus.
  • METHODS: Cases diagnosed between 1998 and 2003 from 39 population-based cancer registries were analyzed.
  • The following anal cancer histologies were included in the analysis: squamous cell, adenocarcinoma, and small cell/neuroendocrine carcinomas.
  • RESULTS: From 1998 through 2003, the annual age-adjusted invasive anal cancer incidence rate was 1.5 per 100,000 persons.
  • Squamous cell carcinoma (SCC) was the most common histology overall, accounting for 18,105 of 21,395 (84.6%) cases of anal cancer.
  • Incidence rates of anal SCC increased 2.6% per year on average.
  • The majority of SCC cases were diagnosed at the in situ or localized stage (58.1%).
  • API were more likely to be diagnosed with regional or distant stage disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
  • CONCLUSIONS: Rates of anal SCC varied by sex, race, and ethnicity.
  • A higher proportion of API were diagnosed at regional/distant stage.
  • Continued surveillance and additional research are needed to assess the potential impact of the HPV vaccine on the anal cancer burden in the US.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):311-20 [12556684.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524 [14605572.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Am J Epidemiol. 1992 Jul 1;136(1):54-8 [1329500.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Am J Epidemiol. 1994 Jul 1;140(1):12-9 [8017399.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):307-13 [9870037.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8 [17065979.001]
  • [Cites] Stat Methods Med Res. 2006 Dec;15(6):547-69 [17260923.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Sex Transm Infect. 2007 Jul;83(4):257-66 [17664359.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1175-86 [17805982.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2841-54 [18980203.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • (PMID = 18980293.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS104103; NLM/ PMC2729501
  •  go-up   go-down


3. Steinbakk A, Malpica A, Slewa A, Gudlaugsson E, Janssen EA, Arends M, Kruse AJ, Yinhua Y, Feng W, Baak JP: High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Anal Cell Pathol (Amst); 2010;33(5):245-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases.
  • OBJECTIVES: to analyze the prognostic value of microsatellite instability (MSI) in a population-based study of FIGO stage 1-4 endometrial endometrioid adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Endometrioid / genetics. Microsatellite Instability

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Cell Oncol (Dordr). 2011 Oct;34(5):457-65 [21547578.001]
  • (PMID = 21079294.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4605578
  •  go-up   go-down


Advertisement
4. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


5. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY: Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol; 2006 Jun 28;12(24):3911-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients.
  • AIM: To quantify the circulating DNA in plasma from patients with hepatocellular carcinoma (HCC) and to evaluate its prognostic value.
  • The circulating DNA level was closely associated with tumor size (P = 0.008) and TNM stage (P = 0.040), negatively associated with the 3-year disease-free survival (DFS) (P = 0.017) and overall survival (OS) (P = 0.001).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / pathology. DNA, Neoplasm / blood. Liver Neoplasms / blood. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1047-52 [12631605.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:17-24 [15251934.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Mol Med. 1995 May;1(4):344-65 [8521292.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):578-84 [10080602.001]
  • [Cites] Hepatology. 1999 Oct;30(4):1027-36 [10498656.001]
  • [Cites] Nature. 1953 Apr 25;171(4356):737-8 [13054692.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):59-64 [10585744.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5723-6 [11479206.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):445-54 [11819809.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1449-53 [12454776.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1579-82 [14571790.001]
  • (PMID = 16804981.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC4087944
  •  go-up   go-down


6. Asahi T, Kondo H, Masuda M, Nishino H, Aratani Y, Naito Y, Yoshikawa T, Hisaka S, Kato Y, Osawa T: Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation. J Biol Chem; 2010 Mar 19;285(12):9282-91
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation.
  • Interestingly, positive mAb8B3 antibody staining was observed in liver tissue from hepatocellular carcinoma patients but not in liver tissue from human cirrhosis patients.

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1631-6 [11172002.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1283-9 [8823292.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2075-81 [9151778.001]
  • [Cites] J Lipid Res. 1997 Jul;38(7):1334-46 [9254060.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):393-7 [9450756.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1809-14 [9806163.001]
  • [Cites] Diabetes. 1999 Jan;48(1):1-9 [9892215.001]
  • [Cites] Biochemistry. 1998 Dec 22;37(51):17923-30 [9922160.001]
  • [Cites] Infect Immun. 1999 Apr;67(4):1828-36 [10085024.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20406-14 [10400665.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51241-9 [15364942.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):24-31 [15589368.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 15;827(1):26-31 [16260376.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3096-104 [16326702.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2006 May;98(5):496-502 [16635109.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):620-6 [16863995.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33440-8 [10559226.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):859-66 [10706276.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2041-51 [11329271.001]
  • [Cites] Biochemistry. 2001 Feb 20;40(7):2052-9 [11329272.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2001 Mar;20(3):251-60 [11393401.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11961-6 [11593004.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40486-96 [11533049.001]
  • [Cites] Free Radic Biol Med. 2001 Dec 1;31(11):1341-51 [11728805.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2081-8 [11733358.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):67-70 [11959105.001]
  • [Cites] Toxicology. 2002 Aug 1;177(1):11-22 [12126792.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46116-22 [12359714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):685-90 [12522148.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8942-50 [12643282.001]
  • [Cites] Anal Biochem. 2003 Jun 15;317(2):201-9 [12758258.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23522-8 [12707270.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36365-72 [12869568.001]
  • [Cites] J Virol. 2004 Aug;78(16):8709-19 [15280479.001]
  • [Cites] Blood. 1990 Aug 15;76(4):655-63 [2200535.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9050-4 [1851162.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4069-77 [8382689.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):541-6 [8397132.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):253-64 [7510036.001]
  • [Cites] Biol Chem Hoppe Seyler. 1994 Feb;375(2):81-8 [8192861.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16542-8 [7622459.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):73-81 [11296483.001]
  • (PMID = 20081197.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Halogens; 0 / Lipopolysaccharides; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.7 / Peroxidase; G9481N71RO / Deoxyguanosine
  • [Other-IDs] NLM/ PMC2838346
  •  go-up   go-down


7. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF: Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer; 2007 Mar 12;96(5):808-14
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
  • We sought to determine expression levels of DDRs in human lung cancer, investigate prognostic determinates, and determine the prevalence of recently reported mutations in these receptor tyrosine kinases.
  • Tumour samples from 146 non-small cell lung carcinoma (NSCLC) patients were analysed for relative expression of DDR1 and DDR2 using quantitative real-time PCR (qRT-PCR).
  • Multivariate analysis revealed DDR1 is an independent favourable predictor for prognosis independent of tumour differentiation, stage, histology, and patient age.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Receptor Protein-Tyrosine Kinases / biosynthesis. Receptors, Mitogen / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA Mutational Analysis. Humans. Male. Mice. Mutation. Polymorphism, Genetic. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R197-205 [16244318.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1928-36 [16424224.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):866-77 [16507902.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):239-48 [16234985.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1108-16 [16626936.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5330-7 [16707459.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):499-507 [16750500.001]
  • [Cites] Clin Lung Cancer. 2006 May;7 Suppl 4:S138-44 [16764754.001]
  • [Cites] Nucleic Acids Res. 2006;34(12):e85 [16840529.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Aug 15;174(4):420-7 [16690978.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):727-35 [11254672.001]
  • [Cites] Circ Res. 2002 Jun 14;90(11):1147-9 [12065315.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):344-51 [12471617.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1289-301 [12628922.001]
  • [Cites] Autoimmunity. 2002 Dec;35(8):521-9 [12765478.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1575-85 [15111304.001]
  • [Cites] Nephron Exp Nephrol. 2004;97(2):e62-70 [15218324.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):413-23 [8382008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5677-81 [8390675.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):569-75 [7845682.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):609-18 [7845687.001]
  • [Cites] Pathobiology. 1997;65(4):195-203 [9396043.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • (PMID = 17299390.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor
  • [Other-IDs] NLM/ PMC2360060
  •  go-up   go-down


8. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


9. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • The T-stage according to the 2001 UICC classification were: 2 T1, 26 T2, 25 T3, and 7 T4.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Stage, age and treatment were all significant indicators of survival in uni- and multivariable analysis.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


11. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • AJCC T-stages were Tis (4%), T1 (8%), T2 (58%) and T3 (29%).
  • One patient had metastatic disease at diagnosis.
  • T-stage and CD4 level in HIV-positive patients predict for LC.
  • T-stage and TT predict for OS.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • Of the 69 patients, 66 received radiotherapy (RT) and 3 with in situ disease were treated by local excision alone without RT.
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890590.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Koh DM, Dzik-Jurasz A, O'Neill B, Tait D, Husband JE, Brown G: Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol; 2008 Feb;81(962):91-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation.
  • The aim of this study was to evaluate the MR findings of anal carcinoma using an external pelvic phased-array coil before and after chemoradiation treatment.
  • 15 patients with carcinoma of the anal canal underwent T(2) weighted and short-tau inversion recovery (STIR) imaging before and after chemoradiation.
  • At pre-treatment imaging, the tumour size and stage, signal intensity and infiltration of adjacent structures were recorded.
  • Pelvic phased-array MR imaging is useful for local staging of anal carcinoma and assessing treatment response.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238920.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Kiran RP, Pokala N, Rottoli M, Fazio VW: Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades. Am Surg; 2009 Feb;75(2):163-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is survival reduced for patients with anal cancer requiring surgery after failure of radiation? Analysis from a population study over two decades.
  • Chemoradiotherapy is the standard treatment for anal cancer.
  • From a prospective population-based database on radiation and surgical therapy, we compare outcomes for patients with anal cancer undergoing rectal resection after radiation with patients undergoing radiation alone.
  • Patients undergoing surgical resection of the rectum after initial radiation (SRT) for squamous cell carcinoma of the anus, anal canal, cloacogenic zone, and overlapping lesions of the rectum and anal canal from 1983 to 2002 were identified from the Surveillance, Epidemiology and End Results database.
  • SRT had more patients with regional stage of disease (66.7 vs 42.4%, P = 0.001).
  • For patients with localized stage, survival for SRT and RT was similar (105 vs 98 months, P = 0.7).
  • For patients with regional stage, survival for SRT and RT was similar (95 vs 83 months, P = 0.6).
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280811.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hammad N, Philip PA, Shields AF, Heilbrun LK, Venkatramanamoorthy R, El-Rayes BF: A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15586

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of squamous cell carcinoma of the anal canal in HIV-positive and HIV-negative patients.
  • : e15586 Background: Human immunodeficiency virus (HIV) infected patients (pts) are at increased risk for squamous cell carcinoma of the anal canal (SCCAC) and the incidence of SCCAC has increased in the era of HAART (highly active antiretroviral therapy).
  • The aim of this study is to describe the outcome, tolerability, and overall survival (OS) in pts with and without HIV infection treated at Karmanos Cancer Institute, at Wayne State University from 1991 to 2007.
  • We collected data regarding HIV status, demographics (age, gender, race), stage at diagnosis, treatment, response to treatment, toxicity, and survival.
  • HIV (+) pts had significantly better stage (p = 0.011) and less frequent reduced chemotherapy dose (p = 0.001).
  • CONCLUSIONS: HIV (+) pts had better stage, received standard chemotherapy dose more often, and had more frequent XRT dermatitis than HIV (-) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962344.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • There was not a significant difference in survival by hospital type or year of diagnosis.
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


22. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • Five-year functional anus-preservation rate was 64%.
  • In multivariate analysis, OS was affected by performance status (P < 0.001), N stage (P = 0.009), and pathological type (P = 0.006).
  • Only N stage (P = 0.001) affected DFS.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Rogers LJ, Howard B, Van Wijk L, Wei W, Dehaeck K, Soeters R, Denny LA: Chemoradiation in advanced vulval carcinoma. Int J Gynecol Cancer; 2009 May;19(4):745-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in advanced vulval carcinoma.
  • INTRODUCTION: Vulval carcinoma is uncommon, affecting approximately 2 per 100,000 women annually.
  • Advanced vulval carcinomas involve midline structures (such as clitoris, urethra, or anus) and/or adjacent pelvic organs or bone, and adequate excision may require urinary diversion, colostomy, or pelvic exenteration.
  • Less morbid and less mutilating therapeutic alternatives have been investigated, particularly chemoradiation, which has shown success in the management of anal carcinomas.
  • This is a retrospective study of the GSH's experience of the use of chemoradiation as primary therapy for women with advanced vulval carcinoma.
  • Other prognostic factors for survival were performance status and tumor stage.
  • Performance status, age, and tumor stage were also associated with survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509582.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure.
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251377.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • Initial tumors were AJCC stage 2 (16 cases), 3A (3 cases), and 4 (1 case).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


29. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F: Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol; 2010 Feb;32(1):39-44
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma.
  • OBJECTIVE: To explore Foxp3, a member of the forkhead box family of transcription factors, which is a major gene for regulatory T (Treg) cell development of CD4+CD25+ or CD8+CD25+ phenotype.
  • Serum prostate-specific antigen levels before and after RP, Gleason score (GS), surgical margin status and pathologic stage were available.
  • CONCLUSION: Treg cells were more common in cancer than in benign prostatic tissue.
  • Patients with prostate cancer show an immunosuppressive regulatory profile, including nonresponsive Tregs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701086.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


32. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
  • In the six operated patients, T stage was correctly assessed in four of six patients by endoscopic ultrasound and in three of six patients by magnetic resonance imaging.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / ultrasonography. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / ultrasonography. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.


34. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ: Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):143-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
  • PURPOSE: Information is limited as to how we should treat invasive anal squamous cell carcinoma (SCC) in patients with chronic immunosuppression, since the majority of clinical studies to date have excluded such patients.
  • The objective of this study is to compare treatment outcomes in immunocompetent (IC) versus immunodeficient (ID) patients with invasive anal SCC treated similarly with combined modality therapy.
  • There were no significant differences in tumor size, T stage, N stage, chemotherapy doses, or radiation doses between the two groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203845.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Kayes OJ, Loddo M, Patel N, Patel P, Minhas S, Ambler G, Freeman A, Wollenschlaeger A, Ralph DJ, Stoeber K, Williams GH: DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma. Clin Cancer Res; 2009 Dec 1;15(23):7335-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.
  • We have analyzed replication licensing factors (RLF), together with DNA ploidy status, to investigate their role in progression of penile squamous cell carcinoma and to assess their utility as novel prognostic tools.
  • Accelerated cell cycle progression was linked to increasing tumor size, stage, and depth of invasion.
  • Our results also identify the DNA replication initiation pathway as a potentially attractive therapeutic target in penile squamous cell carcinoma.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Carcinoma / therapy. Gene Expression Regulation, Neoplastic. Penile Neoplasms / genetics. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Cycle. Cell Cycle Proteins / biosynthesis. Cohort Studies. Geminin. Gene Expression Profiling. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Nuclear Proteins / biosynthesis. Ploidies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Urol. 2005 Mar;173(3):816-9 [15711276.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):476-86 [15928711.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Urol. 2006 May;175(5):1700-4; discussion 1704-5 [16600735.001]
  • [Cites] J Urol. 2006 Jun;175(6):2103-8; discussion 2108 [16697813.001]
  • [Cites] BJU Int. 2006 Sep;98(3):526-31 [16925747.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1384-93 [17406359.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Aug;29(4):185-98 [17879626.001]
  • [Cites] Exp Cell Res. 2007 Oct 15;313(17):3789-99 [17689530.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] J Surg Oncol. 2008 May 1;97(6):487-95 [18425779.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1548-54 [18414413.001]
  • [Cites] Nat Chem Biol. 2008 Jun;4(6):331-2 [18488006.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2855-64 [18843031.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1128-34 [19293805.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] Annu Rev Biochem. 2002;71:333-74 [12045100.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):217-26 [12612656.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1048-54 [12966424.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):1-8 [15183542.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] IARC Sci Publ. 1992;(120):45-173 [1284606.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Br J Urol. 1993 Dec;72(6):941-5 [8306161.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):755-61 [9630184.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • (PMID = 19920109.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6263
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2788529; NLM/ UKMS27727
  •  go-up   go-down


36. Xi Z, LinLin M, Ye T: Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal; 2009;23(6):357-61
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system.
  • OBJECTIVE: To investigate human epididymis protein 4 (HE4) levels in transitional cell carcinoma (TCC) of the urinary system and its relationship with clinicopathological features.
  • There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05).
  • CONCLUSIONS: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / blood. Epididymal Secretory Proteins / metabolism. Urologic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927341.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


37. Zhu X, Ma LL, Ye T: Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal; 2009;23(4):197-201
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.
  • To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation.
  • There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05).
  • [MeSH-major] Antigens, CD / immunology. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / immunology. T-Lymphocytes, Regulatory / immunology. Urologic Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623656.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-7 Receptor alpha Subunit
  •  go-up   go-down


38. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • In the current study, to determine the potential involvement of stathmin in OSCC, we evaluated the state of stathmin protein and mRNA expression in OSCC-derived cell lines and human primary OSCCs.
  • A significant increase in stathmin expression was observed in all OSCC-derived cell lines examined compared to human normal oral keratinocytes.
  • Moreover, stathmin expression status was correlated with the TNM stage grading.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


39. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy; 2007 Jul-Sep;6(3):218-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
  • PURPOSE: To evaluate the outcome after definitive whole pelvis external beam radiotherapy (EBRT) followed by brachytherapy (BT) boost after treatment break vs. external beam boost without break in the treatment of anal carcinoma.
  • METHODS AND MATERIALS: Eighty-one consecutive patients with invasive anal carcinoma were analyzed retrospectively.
  • Concomitant chemotherapy (CT) with mitomycin C was applied during whole pelvis EBRT depending on tumor stage.
  • Pattern of care, local disease control (LC), cancer-specific survival (CSS), overall survival (OS), toxicity, and quality of life (QOL) were assessed.
  • In early stage tumors, (192)Ir-HDR BT boost with CT resulted in a 5-year LC and CSS of 100%.
  • In all patients, BT boost did not result in improved LC, OS, and CSS compared with EBRT boost, despite stage and treatment bias favoring small tumors to be treated with BT.
  • BT boost is most beneficial in early stage tumors but the advantage of BT seems to be limited due to its invasiveness, doctor dependence, and logistic circumstances.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / instrumentation. Carcinoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681244.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Oehler-Jänne C, Seifert B, Lütolf UM, Ciernik IF: Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. Radiat Oncol; 2006;1:29
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.
  • PURPOSE: To investigate the outcome of HIV-seropositive patients under highly active antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in combination with standard chemotherapy (CT).
  • 10 TNM-stage and age matched HIV-seronegative patients (1992-2003) were compared with the 10 HIV-seropositive patients.
  • Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Anus Neoplasms / virology. HIV Infections / complications. HIV Infections / drug therapy. Radiotherapy / methods


41. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Fu S, Arráez-Roman D, Segura-Carretero A, Menéndez JA, Menéndez-Gutiérrez MP, Micol V, Fernández-Gutiérrez A: Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells. Anal Bioanal Chem; 2010 May;397(2):643-54
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative screening of phenolic compounds in olive leaf extracts by hyphenated liquid chromatography and preliminary evaluation of cytotoxic activity against human breast cancer cells.
  • In this work, high-performance liquid chromatography (HPLC) coupled to electrospray time-of-flight mass spectrometry (ESI-TOF-MS) and electrospray ion trap multiple-stage tandem mass spectrometry (ESI-IT-MS(2)) has been applied to screen phenolic compounds in olive leaf extracts.
  • Importantly, olive leaf extracts exhibited dose-dependent inhibitory effects on the metabolic status (cell viability) of three breast cancer models in vitro.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / analysis. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Chromatography, High Pressure Liquid / methods. Olea / chemistry. Phenols / analysis. Phenols / pharmacology
  • [MeSH-minor] Cell Survival / drug effects. Cinnamates / analysis. Cinnamates / isolation & purification. Cinnamates / pharmacology. Female. Flavonoids / analysis. Flavonoids / isolation & purification. Flavonoids / pharmacology. Humans. Iridoids / analysis. Iridoids / isolation & purification. Iridoids / pharmacology. Plant Leaves / chemistry. Pyrans / analysis. Pyrans / isolation & purification. Pyrans / pharmacology. Spectrometry, Mass, Electrospray Ionization / methods. Tandem Mass Spectrometry / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20238105.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cinnamates; 0 / Flavonoids; 0 / Iridoids; 0 / Phenols; 0 / Pyrans; 2O4553545L / oleuropein; 34422-12-3 / elenolic acid; U14A832J8D / cinnamic acid
  •  go-up   go-down


43. Tuna B, Unlu M, Aslan G, Secil M, Yorukoglu K: Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies. Anal Quant Cytol Histol; 2009 Apr;31(2):118-22
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the ability of p63 reactivity to confirm the diagnosis of urothelial carcinomas (UCs) that present clinically as kidney masses and to determine the association of p63 expression with clinicopathologic features in UCs.
  • STUDY DESIGN: The study included 27 patients with renal pelvis UC and 42 patients with renal cell carcinoma (RCC).
  • There was a correlation between p63 expression and tumor stage, grade and survival time (p < 0.0001, = 0.032, = 0.028, respectively).
  • Decreased p63 immunoreactivity was significantly associated with advanced tumor stage and grade. p63 Reactivity appears to be a useful prognostic factor in UC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402389.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


44. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V: Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res; 2010 Oct 15;70(20):7748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.
  • Our approach was to screen for lung cancer by assessing the cheek cells based on emerging genetic/epigenetic data which suggests that the buccal epithelium is altered in lung field carcinogenesis.
  • We performed PWS analysis from microscopically normal buccal epithelial brushings from smokers with and without lung cancer (n = 135).
  • The PWS parameter, disorder strength of cell nanoarchitecture (L(d)), was markedly (>50%) elevated in patients harboring lung cancer compared with neoplasia-free smokers.
  • The performance characteristic was excellent with an area under the receiver operator characteristic curve of >0.80 and was equivalent for both disease stage (early versus late) and histologies (small cell versus non-small cell lung cancers).
  • Our results offer proof of concept that buccal PWS may potentially herald a minimally intrusive prescreening test that could be integral to the success of lung cancer population screening programs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nat Med. 2007 Mar;13(3):361-6 [17334370.001]
  • [Cites] Histol Histopathol. 2007 May;22(5):541-5 [17330809.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):69S-77S [17873161.001]
  • [Cites] BMC Genomics. 2008;9:259 [18513428.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] J Cell Biochem. 2008 Oct 15;105(3):670-7 [18773413.001]
  • [Cites] Acta Cytol. 2008 Sep-Oct;52(5):584-90 [18833822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20118-23 [19073935.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):12-4 [19138931.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):396-403 [19138985.001]
  • [Cites] Opt Lett. 2009 Feb 15;34(4):518-20 [19373360.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5357-63 [19549915.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):1018-20 [19692681.001]
  • [Cites] Cancer Res. 2009 Nov 15;69(22):8629-35 [19887610.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Mar;3(3):266-78 [20179299.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3899-905 [10632318.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5131-6 [15297416.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):254-62 [16447817.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):715-26 [17470739.001]
  • (PMID = 20924114.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA086137-10; United States / NCI NIH HHS / CA / CA086137-10; United States / NCI NIH HHS / CA / U01 CA111257; United States / PHS HHS / / T32ESES007267; United States / NCI NIH HHS / CA / U01CA111257; United States / NCI NIH HHS / CA / U01 CA086137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS275336; NLM/ PMC3703950
  •  go-up   go-down


45. Maw MK, Fujimoto J, Tamaya T: Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer; 2008 Nov 18;99(10):1557-63
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ID-1 histoscores and mRNA levels both significantly (P<0.05) increased in uterine cervical cancers according to clinical stage regardless of histopathological type or lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 [14555767.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1198-203 [15026801.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7317-27 [9372963.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):968-76 [10022839.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):933-8 [16189525.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):186-9 [16595146.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905 [11058077.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5929-33 [11085505.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5703-6 [11479201.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6008-11 [11507043.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1812-22 [11896613.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Mol Carcinog. 2002 Sep;35(1):42-9 [12203366.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):677-82 [12640673.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4498-508 [12881706.001]
  • [Cites] J Pathol. 2003 Aug;200(5):561-7 [12898591.001]
  • [ErratumIn] Br J Cancer. 2009 Jul 21;101(2):377-8
  • (PMID = 19002177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2584935
  •  go-up   go-down


46. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16538643.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


47. Zuo ZG, Song HY, Xu C, Li J, Ni SC, Chen SQ: [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors]. Zhonghua Wai Ke Za Zhi; 2009 Jul 1;47(13):988-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of trans-anal intersphincteric resection and trans-abdominal total mesorectal excision for anus-retained ultra-low rectal tumors].
  • OBJECTIVE: To study the combination of trans-anal intersphincteric resection and transabdominal total mesorectal excision for anus-retained ultra-low rectal tumors.
  • METHODS: Clinical data of 34 ultra-low rectal tumor patients without external anal sphincter involved, who underwent the combination surgery, were retrospectively analyzed.
  • For pathological types, there were 23 cases of adenocarcinoma (9 well differentiated and 14 moderately differentiated), 1 papillary carcinoma, 2 rectal stromal tumor, 5 rectal villous adenoma with neoplasia and 3 giant villous adenoma.
  • For pathological stages, there were 18 cases at stage pTNM I, 5 at IIA, 1 at IIB, 4 at IIIA, 1 at III and for T grading, there were 15 cases at stage T1, 5 at T2, 8 at T3, 1 at T4.
  • Because of the dysfunction of bowel control, bowel frequency varied from 3 to 12 in the early stage after operation, but with the recovery of anus function, bowel frequency decreased and ranged form 1 to 5 times a day and the time of formed bowel control could be more than 5 min in 6-12 months after operation.
  • However, patients underwent total resection of internal anal sphincter still suffered from incontinence of loose stool after 1 year.
  • CONCLUSION: The combination of trans-anal ISR and trans-abdominal TME for anus-retained ultra low rectal tumor is not only coincident with radical tumor principle but also retains the function of anus, on the premise of the strict indication.
  • [MeSH-major] Anal Canal / surgery. Mesentery / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957808.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


49. Tuna B, Yorukoglu K, Mazzucchelli R, Mungan U, Secil M, Montironi R, Kirkali Z: Ezrin immunoreactivity in renal cell carcinomas. Anal Quant Cytol Histol; 2009 Oct;31(5):340-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ezrin immunoreactivity in renal cell carcinomas.
  • OBJECTIVE: To determine ezrin's association with clinicopathologic features and to investigate the possible effects of the presence of ezrin on the differential diagnosis of subtypes of renal cell carcinoma (RCC).
  • STUDY DESIGN: Ezrin reactivity was examined immunohistochemically in tumor tissues obtained from 78 patients who underwent radical nephrectomy for renal cell carcinoma.
  • Correlation between ezrin expression and RCC subtypes was investigated and compared with tumor stage, grade and other clinicopathologic parameters.
  • Ezrin reactivity was observed mainly in conventional, papillary and mucinous tubular spindle cell carcinoma (MTSCC) subtypes of RCC, while none of the chromophobe RCC was positive for ezrin.
  • CONCLUSION: Investigation of ezrin reactivity may be beneficial as an additional diagnostic marker in the differential diagnosis of RCC subtypes.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701102.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / ezrin
  •  go-up   go-down


50. Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, Tang D, Jankowski M, Rybicki BA: Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control; 2009 Dec;20(10):1915-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity.
  • Although the GSTM1 null genotype has been shown to increase prostate cancer mortality in Caucasians, potential associations between GST polymorphisms and prostate cancer biochemical recurrence (BCR) have not been well studied, particularly in African-Americans.
  • Similar associations were observed for advanced stage and more aggressive (high grade or advanced stage) disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] J Urol. 2003 Jan;169(1):157-63 [12478126.001]
  • [Cites] Am J Hum Genet. 2003 Jun;72(6):1492-1504 [12817591.001]
  • [Cites] J Urol. 2003 Apr;169(4):1320-4 [12629352.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Biochemistry. 1996 Oct 22;35(42):13664-72 [8885846.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):8-13 [15880531.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):146-56 [16173036.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45 [17548691.001]
  • [Cites] Pathology. 2007 Jun;39(3):299-304 [17558856.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1271-6 [17698101.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):750-7 [18245535.001]
  • [Cites] Urology. 2008 Jan;71(1):161-7 [18242387.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1 [18707696.001]
  • [Cites] Prostate. 2006 Oct 1;66(14):1535-41 [16921513.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):412-22 [17067754.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):173-82 [10757075.001]
  • [Cites] Cancer. 2000 May 1;88(9):2082-91 [10813720.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):219-25 [11158191.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2302-7 [12436435.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • (PMID = 19568698.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129162-02; United States / NCI NIH HHS / CA / K07-CA129162; United States / NIEHS NIH HHS / ES / R01-ES011126; United States / NIEHS NIH HHS / ES / R01 ES011126; United States / NCI NIH HHS / CA / K07 CA129162-02; United States / NCI NIH HHS / CA / K07 CA129162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


51. Yang P, Sun Z, Chan D, Cartwright CA, Vijjeswarapu M, Ding J, Chen X, Newman RA: Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis; 2008 Nov;29(11):2182-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma (SCC).
  • The effect of Zyflamend on inhibition of LTB(4) formation was further confirmed with in vitro cell-based assay.
  • Adding LTB(4) to RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX and LTA(4) hydrolase, partially blocked antiproliferative effect of Zyflamend.
  • The study suggests that Zyflamend might prevent oral carcinogenesis at the post-initiation stage.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cricetinae. Disease Models, Animal. Rats

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dent Res. 1961 Jan-Feb;40:3-15 [13772812.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):112-9 [10211319.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):2089-96 [15756036.001]
  • [Cites] In Vivo. 2005 Jan-Feb;19(1):247-52 [15796182.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Nutr Cancer. 2005;52(2):202-12 [16201851.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):81-5 [16430737.001]
  • [Cites] Biol Chem. 2006 Apr;387(4):365-72 [16606333.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1902-8 [16632477.001]
  • [Cites] Am J Epidemiol. 2006 Sep 15;164(6):556-66 [16847039.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1842-5 [17003715.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):385-95 [17011176.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):228-36 [17218785.001]
  • [Cites] Nutr Cancer. 2007;57(1):78-87 [17516865.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biochem Suppl. 1993;17F:83-90 [8412211.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):221-4 [10745176.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1307-13 [12151348.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Aug;31(4):419-22 [12361077.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):672-4 [12618872.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1885-97 [12738747.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):99-109 [12895592.001]
  • [Cites] Oral Dis. 2003 Sep;9(5):227-34 [14628889.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):127-37 [14732220.001]
  • [Cites] Oral Oncol. 2004 May;40(5):461-73 [15006617.001]
  • [Cites] Curr Cancer Drug Targets. 2004 May;4(3):267-83 [15134534.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Jun;28(3):155-9 [1966928.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):862-74 [8492315.001]
  • [Cites] Free Radic Biol Med. 1995 Feb;18(2):185-94 [7744301.001]
  • [Cites] Mol Carcinog. 1996 Aug;16(4):197-202 [8784462.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):304-12 [15743693.001]
  • (PMID = 18687669.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101235
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Carcinogens; 0 / Plant Extracts; 0 / Zyflamend; 1HGW4DR56D / Leukotriene B4; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC3697064
  •  go-up   go-down


52. Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G: Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res; 2010 Sep 01;70(17):6815-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
  • Current treatment for late-stage metastatic breast cancer is largely palliative. alpha-Particles are highly potent, short-range radiation emissions capable of sterilizing individual cells with one to three traversals of the cell nucleus.
  • Efficacy in a rat/neu transgenic mouse model of metastatic mammary carcinoma was investigated.
  • We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model.

  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):706-15 [15665617.001]
  • [Cites] Health Phys. 1960 Feb;2:225-38 [13818815.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Curr Pharm Des. 2006;12(36):4729-49 [17168775.001]
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7 [17935286.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Feb;5(2):189-204 [18248318.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):74-81 [18298331.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3873-80 [18483272.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6116-24 [18829490.001]
  • [Cites] Cancer Res. 2009 Dec 1;69(23):8941-8 [19920193.001]
  • [Cites] J Nucl Med. 2010 Feb;51(2):311-28 [20080889.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1935-46 [10565792.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3569-76 [10910070.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):253-60 [14960644.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Expert Opin Ther Targets. 2004 Aug;8(4):335-53 [15268628.001]
  • [Cites] Bioconjug Chem. 1992 Jul-Aug;3(4):342-5 [1390990.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3765-70 [8339289.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107 [8110825.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3352-6 [8012948.001]
  • [Cites] Nucl Med Biol. 1995 Apr;22(3):387-90 [7627155.001]
  • [Cites] J Nucl Med. 1995 Sep;36(9):1639-44 [7658225.001]
  • [Cites] J Leukoc Biol. 1996 Sep;60(3):337-44 [8830790.001]
  • [Cites] Biochemistry. 1997 Jan 7;36(1):66-75 [8993319.001]
  • [Cites] J Nucl Med. 1997 Mar;38(3):489-93 [9074545.001]
  • [Cites] Appl Radiat Isot. 1999 May;50(5):895-904 [10214708.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):87-95 [10528086.001]
  • [Cites] J Biol Chem. 1959 Mar;234(3):466-8 [13641241.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6288-91 [16194090.001]
  • (PMID = 20651254.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113797; United States / NCI NIH HHS / CA / R01 CA113797-04; United States / NCI NIH HHS / CA / R01 CA187037
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoconjugates; 0 / Isothiocyanates; 0 / Liposomes; 0 / Radioisotopes; 142434-84-2 / N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid; 7A314HQM0I / Pentetic Acid; EC 2.7.10.1 / Receptor, ErbB-2; U015TT5I8H / Bismuth
  • [Other-IDs] NLM/ NIHMS248891; NLM/ PMC2977986
  •  go-up   go-down


53. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


54. Moore JS, Cataldo PA, Osler T, Hyman NH: Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. Dis Colon Rectum; 2008 Jul;51(7):1026-30; discussion 1030-1
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medical records were reviewed to determine type of surgery, resection margins, specimen fragmentation, complications, recurrence, lesion type, stage, and size.
  • RESULTS: The groups were similar with respect to age, sex, lesion type, stage, and size.
  • [MeSH-major] Adenoma / surgery. Carcinoid Tumor / surgery. Carcinoma in Situ / surgery. Colonic Polyps / surgery. Colonoscopy / methods. Microsurgery / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anal Canal. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481147.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Yamashita S, Masui T, Katayama M, Sato K, Yoshizawa N, Seo H, Sakahara H: T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences. J Magn Reson Imaging; 2007 Mar;25(3):511-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T2-weighted MRI of rectosigmoid carcinoma: comparison of respiratory-triggered fast spin-echo, breathhold fast-recovery fast spin-echo, and breathhold single-shot fast spin-echo sequences.
  • MATERIALS AND METHODS: Forty patients (stage: pT0, 1; pTis-2, 15; pT3-4, 24) were included in the study.
  • All examinations were performed on a 1.5T magnet with a phased-array coil and the patients were studied in the prone position with per-anal air injection.
  • CONCLUSION: The BH-FRFSE sequence may be the first choice for rectosigmoid T2W imaging in the prone position with per-anal air injection for patients who can hold their breath stably.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis. Respiration. Sigmoid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Artifacts. Diagnosis, Differential. Echo-Planar Imaging / methods. Female. Humans. Male. Middle Aged. Observer Variation. Prospective Studies. ROC Curve

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326094.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, Yamakado M, Imamura F, Kodama K: Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer; 2010;10:690
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
  • BACKGROUND: The amino-acid balance in cancer patients often differs from that in healthy individuals, because of metabolic changes.
  • This study investigated the use of plasma amino-acid profiles as a novel marker for screening non-small-cell lung cancer (NSCLC) patients.
  • The obtained model (including alanine, valine, isoleucine, histidine, tryptophan and ornithine concentrations) performed well, with an area under the curve of the receiver-operator characteristic curve (ROC_AUC) of >0.8, and allowed NSCLC patients and controls to be discriminated regardless of disease stage or histological type.
  • [MeSH-major] Amino Acids / blood. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Mass Screening / methods. Metabolomics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr Biochem. 2003 Mar;14(3):133-8 [12742540.001]
  • [Cites] J Proteome Res. 2010 Sep 3;9(9):4620-7 [20701291.001]
  • [Cites] Adv Exp Med Biol. 2003;527:363-6 [15206751.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5839-49 [15313928.001]
  • [Cites] Surgery. 1975 Sep;78(3):276-90 [807982.001]
  • [Cites] Cancer. 1985 Jan 1;55(1 Suppl):225-9 [3880655.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1181-6 [3926295.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):355-60 [3383136.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286-98 [3292798.001]
  • [Cites] Cancer. 1992 May 1;69(9):2343-8 [1562982.001]
  • [Cites] Anticancer Res. 1995 Mar-Apr;15(2):507-10 [7763031.001]
  • [Cites] Am J Clin Nutr. 2005 May;81(5):1142-6 [15883440.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):4988s-4992s [16000601.001]
  • [Cites] Oncology. 2005;68(4-6):471-8 [16020977.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):513S-519S [16470023.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Intern Med. 2008;47(13):1199-205 [18591840.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):49-53 [19057187.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):799-800 [19212391.001]
  • [Cites] Science. 2009 Feb 13;323(5916):865 [19213886.001]
  • [Cites] Rapid Commun Mass Spectrom. 2009 May;23(10):1483-92 [19350529.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4918-25 [19458066.001]
  • [Cites] Anal Chem. 2009 Jul 1;81(13):5172-9 [19480430.001]
  • [Cites] J Proteome Res. 2009 Oct;8(10):4844-50 [19678709.001]
  • [Cites] J Proteome Res. 2010 Jan;9(1):319-32 [19908917.001]
  • [Cites] Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20 [20143319.001]
  • [Cites] BMC Bioinformatics. 2010;11 Suppl 2:S4 [20406502.001]
  • [Cites] Gynecol Oncol. 2010 Jun;117(3):440-5 [20334903.001]
  • [Cites] Biomed Chromatogr. 2010 Jul;24(7):683-91 [19830681.001]
  • [Cites] J Proteome Res. 2010 Jun 4;9(6):2988-95 [20337499.001]
  • [Cites] Bioinformatics. 2004 Apr 12;20(6):959-69 [14751977.001]
  • (PMID = 21176209.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3014908
  •  go-up   go-down


57. Alvarez G, Perry A, Tan BR, Wang HL: Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol; 2006 Jul;19(7):942-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification.
  • The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated.
  • In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers.
  • There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times.
  • These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification.
  • [MeSH-major] Anus Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / metabolism. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648870.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


58. Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr; 2005 Dec 1;40(4):451-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic.
  • Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence is increased among the immunosuppressed.
  • Men were more likely to be diagnosed with early-stage disease, but they were less likely than women to receive radiation therapy.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / epidemiology


59. Fariña-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol (Amst); 2010;33(1):1-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
  • AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences.
  • With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.
  • PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected.
  • RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found.
  • CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966539.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4605551
  •  go-up   go-down


60. Ascani G, Balercia P, Messi M, Lupi L, Goteri G, Filosa A, Stramazzotti D, Pieramici T, Rubini C: Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):13-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in oral squamous cell carcinoma.
  • Based on these results, microvessel density was evaluated, in the present study, in 64 cases of squamous cell carcinoma of the oral cavity, using immunohistochemical analysis with anti-CD34 monoclonal antibody.
  • Possible correlations between microvessel density and clinico-pathological parameters were analysed, such as: age, sex, tumour localization and size, TNM stage and histological grading.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):183-92 [11564894.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):463-8 [11876537.001]
  • [Cites] Head Neck. 2002 Jul;24(7):643-50 [12112537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Sci Am. 1976 May;234(5):58-64, 70-3 [1273568.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Eur J Cancer. 1993;29A(8):1141-5 [8390846.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):678-87 [7507798.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Oct;111(4):417-22 [7524005.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):373-80 [7526718.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008 [7543156.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1417-22 [7544566.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):865-8 [8703391.001]
  • [Cites] Head Neck. 1996 Jul-Aug;18(4):343-6 [8780945.001]
  • [Cites] Head Neck. 1997 Jul;19(4):276-80 [9213105.001]
  • [Cites] J Pathol. 1997 Sep;183(1):39-43 [9370945.001]
  • [Cites] Oral Oncol. 1997 Sep;33(5):369-74 [9415339.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):659-64 [9426404.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • (PMID = 16080310.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD31
  • [Other-IDs] NLM/ PMC2639850
  •  go-up   go-down


61. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM: Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer; 2006;6:68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
  • We sought to determine whether ICAT technology could quantify and identify differential expression of tumor-specific proteins in nipple aspirate fluid (NAF) from the tumor-bearing and contralateral disease-free breasts of patients with unilateral early-stage breast cancer.
  • METHODS: Paired NAF samples from 18 women with stage I or II unilateral invasive breast carcinoma and 4 healthy volunteers were analyzed using ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), liquid chromatography, and MS.
  • Western blot analysis of NAF from an independent sample set from 12 women (8 with early-stage breast cancer and 4 healthy volunteers) was also performed.
  • Western blot analysis of pooled samples of NAF from healthy volunteers versus NAF from women with breast cancer confirmed the overexpression of vitamin D-binding protein in tumor-bearing breasts.
  • Proteomic screening techniques using ICAT and NAF may be used to find markers for diagnosis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Mass Spectrometry / methods. Nipples / secretion. Proteomics / methods. Vitamin D-Binding Protein / metabolism
  • [MeSH-minor] Blotting, Western. Body Fluids / metabolism. Carbon Isotopes. Carcinoma / diagnosis. Carcinoma / metabolism. Chromatography, Liquid. Female. Humans. Middle Aged. Peptides / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 Oct;3(10):1863-73 [14625848.001]
  • [Cites] Mol Cell Proteomics. 2003 Nov;2(11):1198-204 [14506205.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):380-8 [15025535.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14129-39 [14729674.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20127-36 [14988394.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):520-3 [15157176.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Genome Biol. 2004;5(8):R54 [15287976.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2652-6 [15309713.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6402-9 [15374947.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):615-22 [15243804.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4764-7 [6254651.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Aug 31;101(4):1131-8 [6272774.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5121-4 [6272989.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):149-57 [15692757.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Mol Biotechnol. 2005 Mar;29(3):233-44 [15767701.001]
  • [Cites] Proteomics. 2005 May;5(7):1797-805 [15825149.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):349-55 [12590263.001]
  • [Cites] N Engl J Med. 1992 Jul 30;327(5):319-28 [1620171.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):357-70 [7881112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Anal Chem. 1997 Apr 15;69(8):1518-24 [9109352.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):567 [10950239.001]
  • [Cites] Curr Opin Biotechnol. 2000 Aug;11(4):413-8 [10975463.001]
  • [Cites] Curr Opin Chem Biol. 2000 Oct;4(5):489-94 [11006534.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:312-5 [11193768.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1462-7 [11230492.001]
  • [Cites] Breast Cancer Res. 2000;2(2):92-9 [11250698.001]
  • [Cites] Anal Chem. 2001 Mar 1;73(5):978-86 [11289445.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4782-93 [11532942.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • [Cites] J Am Soc Mass Spectrom. 2001 Dec;12(12):1238-46 [11766750.001]
  • [Cites] Dis Markers. 2001;17(4):301-7 [11790897.001]
  • [Cites] J Mass Spectrom. 2002 Jan;37(1):1-14 [11813306.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):378-87 [11843848.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Biochemistry. 2002 May 28;41(21):6714-22 [12022875.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5088-96 [12356725.001]
  • [Cites] Curr Opin Chem Biol. 2002 Oct;6(5):666-75 [12413552.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2276-82 [12436432.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):749-54 [12576445.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2159-65 [12720356.001]
  • [Cites] Breast Cancer Res. 2003;5(4):R82-7 [12817998.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Jul;14(7):696-703 [12837591.001]
  • [Cites] Breast Cancer Res. 2003;5(6):320-8 [14580250.001]
  • [Cites] Int J Biol Markers. 2003 Oct-Dec;18(4):241-72 [14756541.001]
  • (PMID = 16542425.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Isotopes; 0 / Peptides; 0 / Vitamin D-Binding Protein
  • [Other-IDs] NLM/ PMC1431555
  •  go-up   go-down


62. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM: Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol; 2010 Feb;33(1):47-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy for squamous cell carcinoma of the anal canal.
  • PURPOSE: To review the outcomes of definitive radiotherapy (RT) alone or combined with chemotherapy (CT) in the treatment of squamous cell carcinoma of the anal canal.
  • Distribution according to T stage was: T1, 11 (16%); T2, 29 (42%); T3, 21 (30%); and T4, 8 (12%).
  • Distribution according to N stage was: N0, 53 (77%); N1, 3 (4%); N2, 7 (10%); and N3, 6 (9%).
  • The 5-year cause-specific and overall survival rates were: stage I, 100% and 64%; stage II, 86% and 70%; stage III, 80% and 76%; and overall, 87% and 71%, respectively.
  • [MeSH-major] Anal Canal / radiation effects. Antineoplastic Agents / therapeutic use. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704368.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


63. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • CONCLUSIONS: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


64. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. J Pharm Biomed Anal; 2008 Nov 4;48(3):606-11
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early stage of colorectal carcinogenesis on account of its genotoxic potential.
  • These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in cancer cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the stage of dysregulation of lipid peroxidation and, finally, the stage of carcinoma development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619756.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


65. Lorentzen A, Vogel LK, Lewinsky RH, Saebø M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T, Kure EH, Mitchelmore C: Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer; 2007 Oct 12;7:192
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.
  • BACKGROUND: It has recently been shown that NDRG2 mRNA is down-regulated or undetectable in several human cancers and cancer cell-lines.
  • The aim of this study has been to examine NDRG2 mRNA expression in colon cancer.
  • When comparing adenomas/carcinomas with adjacent normal tissue from the same individual, NDRG2 expression levels were significantly reduced in both high-risk adenoma (p < 0.001) and in colorectal carcinoma (p < 0.001).
  • There was a trend for NDRG2 levels to decrease with increasing Dukes' stage (p < 0.05).
  • CONCLUSION: Our results demonstrate that expression of NDRG2 is down-regulated at a late stage during colorectal carcinogenesis.
  • Future studies are needed to address whether NDRG2 down-regulation is a cause or consequence of the progression of colorectal adenomas to carcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):193-201 [16645205.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Proteins. 2002 May 1;47(2):163-8 [11933063.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):342-7 [12845671.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):413-8 [14572661.001]
  • [Cites] Neurobiol Dis. 2004 Jun;16(1):48-58 [15207261.001]
  • [Cites] Mech Dev. 1999 May;83(1-2):39-52 [10381566.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3518-21 [15526377.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):672-5 [16042571.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):111-21 [16247483.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39159-68 [17050536.001]
  • (PMID = 17935612.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NDRG2 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2099434
  •  go-up   go-down


66. Hegele A, Hofmann R, Kosche B, Kropf J: Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma. Biomark Insights; 2007 Feb 07;2:1-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.
  • Reliable markers for both renal cell carcinoma (RCC) and transitional cell carcinoma of the bladder (TCC) are lacking.During tumor progression and invasion components of extracellular matrix (ECM) are degraded and parts of these different components are detectable in plasma.
  • Similar results were found in RCC with significant elevated cFN levels in metastatic RCC (p < 0.005) compared to localized stage of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):30-5 [15912517.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Br J Cancer. 1997;76(6):777-83 [9310245.001]
  • [Cites] Eur Urol. 1997;31(1):40-8 [9032533.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):364-71 [8903479.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):83-91 [7589259.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):173-89 [8548867.001]
  • [Cites] J Hepatol. 1995;22(2 Suppl):77-81 [7665854.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):578-82 [7880741.001]
  • [Cites] Clin Chem. 1995 Sep;41(9):1283-7 [7656438.001]
  • [Cites] J Urol. 1993 Feb;149(2):268-71 [8426398.001]
  • [Cites] Jpn J Cancer Res. 1992 Dec;83(12):1327-33 [1483947.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Anal Biochem. 1991 Aug 15;197(1):258-65 [1952074.001]
  • [Cites] J Cell Biol. 1986 Nov;103(5):1671-7 [3023390.001]
  • [Cites] Arch Dermatol. 1988 Feb;124(2):221-5 [3341802.001]
  • [Cites] J Cell Biol. 1982 Nov;95(2 Pt 1):369-77 [6128348.001]
  • [Cites] Tumour Biol. 2004 May-Jun;25(3):111-6 [15361707.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1496-500 [15371878.001]
  • [Cites] Urol Res. 2003 Feb;30(6):363-6 [12599015.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):826-30 [12181267.001]
  • [Cites] Urol Res. 2002 May;30(2):126-9 [12086018.001]
  • [Cites] Eur Urol. 2001 Mar;39(3):292-9 [11275722.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):889-94 [11948468.001]
  • [Cites] Thromb Res. 2002 Jan 1;105(1):37-41 [11864705.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78 [11514784.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3585-94 [10999749.001]
  • [Cites] Urol Int. 2000;64(4):198-201 [10895085.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):199-205 [10822136.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] Clin Chim Acta. 2006 Oct;372(1-2):83-93 [16730689.001]
  • [Cites] J Thromb Haemost. 2006 Jul;4(7):1461-9 [16839338.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1193-5 [16709950.001]
  • [Cites] Curr Pharm Des. 2005;11(7):881-91 [15777241.001]
  • (PMID = 19662188.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717843
  • [Keywords] NOTNLM ; Biological markers / Extracellular matrix / Invasion / TRFIA / tumor progression
  •  go-up   go-down


67. Looi ML, Dali AZ, Ali SA, Ngah WZ, Yusof YA: Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Anal Quant Cytol Histol; 2008 Apr;30(2):63-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix.
  • STUDY DESIGN: A total of 131 cervical specimens, consisting of normal cervical epithelium (n = 43), cervical intraepithelial neoplasia (CIN) lesions (n =40) and cervical squamous cell carcinomas (SCCs) (n = 48) were examined immunohistochemically in paraffin sections for expression of p53, bcl-2 and Ki-67.
  • CONCLUSION: HGCIN is an early stage to demonstrate the alteration of bcl-2 and Ki-67 expressions.


68. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol; 2007;8:47
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
  • No conclusive systematic study comparing the suitability of different candidate reference genes in clear cell renal cell carcinoma has been published to date.
  • RESULTS: The expression of the potential reference genes was examined in matched malignant and non-malignant tissue specimens from 25 patients with clear cell renal cell carcinoma.
  • The expression of all genes did not depend on age, sex, and tumour stage.
  • CONCLUSION: Our study demonstrated the suitability of the two housekeeping genes PPIA and TBP as endogenous reference genes when comparing malignant tissue samples with adjacent normal tissue samples from clear cell renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Genes, Neoplasm / genetics. Kidney Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Thorax. 2002 Sep;57(9):765-70 [12200519.001]
  • [Cites] Yakugaku Zasshi. 2003 May;123(5):369-75 [12772594.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):356-60 [12787429.001]
  • [Cites] Nat Genet. 2003 Dec;35(4):292-3 [14647279.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):97-105 [14675040.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] J Urol (Paris). 1994;100(4):189-95 [7868931.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Mol Diagn. 2004;8(2):107-13 [15527325.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2308-14 [15569320.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1043-52 [15592504.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Mol Endocrinol. 2005 Jun;34(3):597-601 [15956331.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Mol Med (Berl). 2005 Dec;83(12):1014-24 [16211407.001]
  • [Cites] BMC Mol Biol. 2006;7:3 [16448564.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Int J Urol. 2006 Mar;13(3):265-70 [16643621.001]
  • [Cites] Mar Biotechnol (NY). 2006 Jul-Aug;8(4):398-408 [16676145.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):36-43 [16844072.001]
  • [Cites] BMC Mol Biol. 2006;7:33 [17026756.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Mol Endocrinol. 2002 Aug;29(1):23-39 [12200227.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):163-74 [12419855.001]
  • (PMID = 17559644.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM9 protein, human
  • [Other-IDs] NLM/ PMC1913536
  •  go-up   go-down


69. Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I: Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis; 2005 Sep;20(5):440-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
  • BACKGROUND AND AIMS: Preoperative radiotherapy (PRT) for rectal carcinoma has been shown to cause tumour regression and increase local control and patient survival.
  • METHODS: Depending on the tumour stage (uT), as defined by preoperative endorectal ultrasound (ERUS), fixity and distance from the anal verge, 126 patients with rectal cancer underwent either surgery alone, or received short-course 25-Gy radiotherapy or long-course 50-Gy radiotherapy combined with 5-fluorouracil (5-FU) before surgery.
  • TRG in each group was assessed and compared with the downstaging, defined as a change in preoperative uT stage and pathologic stage (pT).
  • In contrast, T-stage downstaging was similar in both groups and did not correlate with the TRG results (p=0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856263.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
  • OBJECTIVE: To investigate the diversity within invasive ductal carcinoma (IDC) and prostatic adenocarcinoma (PCa) by evaluating immunohistochemical expression of heat shock protein 47 (HSP47) and fascin, the molecules that are related to desmoplasia and invasion, and analyze its correlation with clinicopathologic parameters.
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701077.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins
  •  go-up   go-down


71. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H: [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr; 2006 Aug 25;131(34-35):1849-52
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The data were collected on all AIDS- and not-AIDS-defined haematological malignancies and all AIDS- and not-AIDS-defined solid malignant tumors in HIV-positive patients, as well as on time of diagnosis of the malignancy, tumor stage, tumor treatment and response to treatment.
  • 180 malignant neoplasms (47%) were AIDS-defined: 89 Kaposi's sarcomas, 82 aggressive B-cell lymphomas and 9 invasive cervical carcinomas.
  • The aggressive B-cell lymphomas consisted of 19 cases of Burkitt's lymphoma, 8 of Castleman's disease and 12 of primary cerebral malignant lymphoma.
  • Of the 200 (52.6%) not-AIDS-defined malignant tumors 133 were 133 solid tumors, 40 of them anal carcinoma (20% of all not-AIDS-defined malignancies) and 67 haematological malignancies, 22 of these Hodgkin's lymphoma (11.0% of all not-AIDS-defined malignancies).
  • The incidence of anal carcinoma is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's lymphoma 19 (95% CI 12-28) per 100 000 patient-years.
  • Of special note is the high incidence of anal carcinoma and Hodgkin's lymphoma, compared with their incidence among the entire German population.
  • [MeSH-major] Anus Neoplasms / epidemiology. HIV Infections / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / virology
  • [MeSH-minor] Carcinoma / epidemiology. Female. Germany / epidemiology. Humans. Incidence. Male. Retrospective Studies. Sex Factors. Surveys and Questionnaires


72. Engin G: Endosonographic imaging of anorectal diseases. J Ultrasound Med; 2006 Jan;25(1):57-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Rectal carcinoma appears on endorectal sonography as a low-echogenicity lesion that abruptly interrupts the normal sequence of layers.
  • The internal anal sphincter is seen very clearly on endoanal sonography, and it is easy to appreciate atrophy and small tears of this sphincter.
  • Endoanal sonography cannot accurately show thinning of the external anal sphincter.
  • CONCLUSIONS: Endosonography can accurately stage primary rectal tumors and assess the internal anal sphincter.
  • However, magnetic resonance imaging can be used a complementary modality to endosonography, especially for evaluation of external anal sphincter atrophy and deep pelvic inflammation.
  • [MeSH-major] Anus Diseases / ultrasonography. Endosonography / methods. Rectal Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371556.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


73. Kurt M, Ozkan L, Ercan I, Kahraman S, Zorluoglu A, Gurel S, Memik F, Engin K: Preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Hepatogastroenterology; 2005 Jul-Aug;52(64):1095-100
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
  • BACKGROUND/AIMS: To determine the percentage of responders and the resectability rate for patients with locally advanced carcinoma of the rectum treated by infusional 5-fluorouracil chemotherapy and pelvic radiation.
  • METHODOLOGY: Twenty-four patients with a diagnosis of locally advanced unresectable rectal cancer received preoperative 5-fluorouracil by intravenous infusion at the dose of 250-300mg/m2/day concurrent with pelvic radiation (median 50.4 Gy/28 fractions).
  • Surgery was performed with a mean delay of 15 days after completion of irradiation and included 11 abdominoperineal resections and five anal sphincter-preserving procedures.
  • There was a significant difference in the rate of local control based on the distance of the tumor from the anal verge (>5.4cm; p=0.046).
  • With metastasis-free survival as the endpoint, only stage (p=0.027) was a statistically significant prognostic factor.
  • CONCLUSIONS: The favorable influence of higher doses of preoperative radiotherapy on pathologic stage has been observed.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001638.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Pasetto LM, Friso ML, Pucciarelli S, Basso U, Toppan P, Rugge M, Sinigaglia G, Nitti D, Sotti G, Monfardini S: Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis. Anticancer Res; 2007 Mar-Apr;27(2):1079-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
  • BACKGROUND: Rectal cancer is commonly diagnosed at a precocious stage, but for patients presenting at diagnosis with stage IV disease the best treatment is still undefined.
  • The purpose of this study was to review the feasibility and outcome of multimodality treatment of rectal cancer patients metastatic at diagnosis.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 40 patients with histologically proven stage IV rectal adenocarcinoma (< 12 cm from the anal verge) were examined.
  • CONCLUSION: The best treatment on diagnosis of metastatic rectal cancer is a multimodality CHT-RT approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


75. Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I: Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Anal Quant Cytol Histol; 2008 Oct;30(5):297-305
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system.
  • OBJECTIVE: To evaluate differences in chromosomal aberrations in recurrent urothelial cancer (UC) of the bladder between the World Health Organization (WHO) 1973 and 2004 classification a retrospective study was performed.
  • STUDY DESIGN: Primary and recurrent UCs of the bladder of 22 patients diagnosed at the Institute of Pathology, Medical University of Innsbruck were analyzed by comparative genomic hybridization, fluorescence in situ hybridization and immunohistochemistry (Ki-67, p53).
  • Grade 2 tumors, reclassified as high-grade tumors, were of higher stage and showed aberrations usually associated with higher grade and poor outcome (1p+, 16p+, -2 and -5q).

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980162.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


77. Chiappa A, Biffi R, Zbar AP, Luca F, Crotti C, Bertani E, Biella F, Zampino G, Orecchia R, Fazio N, Venturino M, Crosta C, Pruneri GC, Grassi C, Andreoni B: Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003. Int J Colorectal Dis; 2005 May;20(3):221-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003.
  • BACKGROUND AND AIMS: This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution.
  • PATIENTS AND METHODS: One hundred and fifty-three patients who had undergone elective curative surgical resection of rectal cancer within 6 cm of the anal verge were included.
  • On multivariate analysis type of surgery (P=0.025) and tumour stage (P=0.043), were associated with local recurrence, but only stage was a significant prognosticator of overall survival (P=0.0006).
  • CONCLUSION: With the practice of total mesorectal excision, APR was still necessary in 40% of patients with rectal cancer within 6 cm of the anal verge.
  • [MeSH-major] Carcinoma / surgery. Digestive System Surgical Procedures / methods. Postoperative Care / methods. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602647.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Wang X, Zheng B, Zhang RR, Li S, Chen X, Mulvihill JJ, Lu X, Pang H, Liu H: Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis. Technol Cancer Res Treat; 2010 Jun;9(3):231-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of fluorescent in situ hybridization (FISH) labeled genetic biomarkers in assisting cervical cancer diagnosis.
  • The numerical and/or structural deviation of some chromosomes (i.e., monosomy and _polysomy of chromosomes 3 and X) are routinely used as positive genetic biomarkers to diagnose cervical cancer and predict the disease progression.
  • Among the available diagnostic methods to analyze the aneusomy of chromosomes 3 and X, fluorescence in situ hybridization (FISH) technology has demonstrated significant advantages in assisting clinicians to more accurately detect and diagnose cervical carcinoma at an early stage, in particular for the women at a high risk for progression of low-grade and high-grade squamous intra-epithelium lesions (LSIL and HSIL).
  • In order to increase the diagnostic accuracy, consistency, and efficiency from that of manual FISH analysis, this study aims to develop and test an automated FISH analysis method that includes a two-stage scheme.
  • In the first stage, an interactive multiple-threshold algorithm is utilized to segment potential interphase nuclei candidates distributed in different intensity levels and a rule-based classifier is implemented to identify analyzable interphase cells.
  • In the second stage, FISH labeled biomarker spots of chromosomes 3 and X are segmented by a top-hat transform.
  • The experimental results of four test cases showed high agreement of FISH analysis results between the automated scheme and the cytogeneticist's analysis including 92.7% to 98.7% agreement in cell segmentation and 4.4% to 11.0% difference in cell classification.
  • This preliminary study demonstrates the feasibility of potentially applying the automatic FISH analysis method to expedite the screening and detecting cervical cancer at an early stage.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Automation. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / genetics. Female. Humans. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Nov;164(5):1768-75 [11025767.001]
  • [Cites] Cytometry. 1997 May 1;28(1):1-10 [9136750.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):359-65 [11169960.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):852-4 [12048273.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):301-7 [12768634.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):310-5 [14579298.001]
  • [Cites] Anal Cell Pathol. 1997 May;13(3):137-46 [9223756.001]
  • [Cites] Cytometry. 1997 Aug 1;28(4):289-97 [9266748.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):525-35 [9341866.001]
  • [Cites] Blood. 1998 May 1;91(9):3357-65 [9558393.001]
  • [Cites] Cytometry. 1999 Aug 1;36(4):279-93 [10404143.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):41-6 [10502423.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1229-38 [15793301.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):716-23 [15981811.001]
  • [Cites] Cytometry A. 2005 Sep;67(1):18-26 [16082715.001]
  • [Cites] J Med Virol. 2006 Jan;78(1):117-24 [16299730.001]
  • [Cites] Cytometry A. 2006 Jun;69(6):506-14 [16646048.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3032-8 [16809727.001]
  • [Cites] J Pathol. 2006 Dec;210(4):412-9 [17054308.001]
  • [Cites] Technol Cancer Res Treat. 2008 Jun;7(3):161-74 [18473488.001]
  • [Cites] J Biomed Opt. 2009 Mar-Apr;14(2):021002 [19405715.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1624-9 [15196550.001]
  • [Cites] Pathol Oncol Res. 2004;10(3):142-8 [15448749.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 5;86(1):6-7 [8271287.001]
  • [Cites] Cytometry. 1996 Jun 1;24(2):158-66 [8725665.001]
  • [Cites] Cytometry. 2001 Feb 1;43(2):87-93 [11169572.001]
  • (PMID = 20441233.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136700; United States / NCI NIH HHS / CA / R01 CA136700-01; United States / NCI NIH HHS / CA / CA136700
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS220245; NLM/ PMC2916642
  •  go-up   go-down


79. Han JG, Wei GH, Gao ZG, Zheng Y, Wang ZJ: Intersphincteric resection with direct coloanal anastomosis for ultralow rectal cancer: the experience of People's Republic of China. Dis Colon Rectum; 2009 May;52(5):950-7
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intersphincteric resection with direct coloanal anastomosis for ultralow rectal cancer: the experience of People's Republic of China.
  • PURPOSE: The purpose of this study was to evaluate the oncologic and functional outcomes of intersphincteric resection in ultralow rectal cancer.
  • METHODS: From 2000 to 2007, intersphincteric resection with total mesorectal excision was performed in 40 patients with very low rectal cancer (total intersphincteric resection in 5 patients, partial intersphincteric resection in 23 patients, and partial intersphincteric resection with partial dentate line preservation [modified partial intersphincteric resection] in 12 patients).
  • The preoperative tumor stage was T12N01M0.
  • A temporary diverting stoma may be beneficial to improve anal function.
  • Modified partial intersphincteric resection under the precondition of radical resection yielded better anal function and a lower rate of incontinence.
  • [MeSH-major] Anal Canal / surgery. Anastomosis, Surgical / methods. Colon / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Defecation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Surgical Stomas. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502861.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal cancer located <12 cm from the anal verge were recruited for this pilot study.
  • Pretreatment tumor size and stage were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
  • [MeSH-minor] Adult. Aged. Cell Hypoxia. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


81. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


82. Li CS, Wan DS, Pan ZZ, Zhou ZW, Chen G, Wu XJ, Li LR, Lu ZH, Ding PR, Li Y: [Multivariate prognostic analysis of patients with low and middle rectal cancer after curative resection]. Ai Zheng; 2006 May;25(5):587-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis of patients with low and middle rectal cancer after curative resection].
  • BACKGROUND & OBJECTIVE: The incidence of low and middle rectal cancer is high in China.
  • This study was to evaluate the correlation of clinicopathologic features to the prognosis in low and middle rectal cancer.
  • METHODS: The clinicopathologic data of 599 patients with low and middle rectal cancer, treated from 1990 to 1999 in Cancer Center of Sun Yat-sen University, were analyzed retrospectively.
  • Univariate analysis showed that local recurrence, perioperative blood transfusion, lymph node metastasis, T stage, histology, macropathology, operation pattern, and distance from anal margin were correlated to prognosis (P<0.05).
  • Multivariate analysis showed that local recurrence, perioperative blood transfusion, lymph node metastasis, and T stage were independent prognostic factors (P<0.01).
  • CONCLUSIONS: Local recurrence, perioperative blood transfusion, lymph node metastasis, and T stage are important prognostic factors of low and middle rectal cancer.
  • LAR has become the preferred option in curative surgery for low and middle rectal cancer.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Blood Transfusion. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687079.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Courter LA, Luch A, Musafia-Jeknic T, Arlt VM, Fischer K, Bildfell R, Pereira C, Phillips DH, Poirier MC, Baird WM: The influence of diesel exhaust on polycyclic aromatic hydrocarbon-induced DNA damage, gene expression, and tumor initiation in Sencar mice in vivo. Cancer Lett; 2008 Jun 28;265(1):135-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the influence of diesel exhaust particulate matter on PAH-induced cytochrome P450 (CYP) activity, PAH-DNA adduct formation, expression of certain candidate genes and the frequency of tumor initiation in the two-stage Sencar mouse model.
  • The applied diesel particulate matter (SRM(1975)) altered the tumor initiating potency of DBP: a statistically significant decrease in overall tumor and carcinoma burden was observed following 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), compared with DBP exposure alone.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIBENZO(A,L)PYRENE .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2083-9 [7554058.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2979-84 [8674051.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):442-8 [17490615.001]
  • [Cites] Mutat Res. 2007 Dec 1;625(1-2):72-82 [17612574.001]
  • [Cites] Nat Protoc. 2007;2(11):2772-81 [18007613.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1797-810 [17944540.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):653-61 [10753200.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1742-9 [11114312.001]
  • [Cites] Hum Exp Toxicol. 2000 Oct;19(10):573-95 [11211997.001]
  • [Cites] Environ Health Perspect. 2001 Jan;109(1):71-4 [11171528.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2727-31 [11289154.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):1077-86 [11408352.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):121-7 [11668486.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] JAMA. 2002 Mar 6;287(9):1132-41 [11879110.001]
  • [Cites] Mutat Res. 2002 Mar 25;515(1-2):85-98 [11909757.001]
  • [Cites] Chemosphere. 2002 Apr;47(1):57-64 [11996136.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):241-6 [12011483.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 [12223276.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1127-35 [12230405.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1937-45 [12419844.001]
  • [Cites] Environ Res. 2003 Jul;92(3):191-6 [12804515.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):1-6 [14720319.001]
  • [Cites] Glycoconj J. 2004;19(7-9):557-63 [14758080.001]
  • [Cites] Toxicol In Vitro. 2004 Jun;18(3):377-91 [15046786.001]
  • [Cites] Environ Mol Mutagen. 2004;44(2):99-107 [15278913.001]
  • [Cites] J Invest Dermatol. 1974 Oct;63(4):343-9 [4424714.001]
  • [Cites] Int J Environ Anal Chem. 1981;9(2):93-144 [7012053.001]
  • [Cites] Carcinogenesis. 1982;3(4):371-5 [6284398.001]
  • [Cites] Cancer Lett. 1984 Oct;24(3):327-33 [6437667.001]
  • [Cites] Mol Pharmacol. 1997 Dec;52(6):974-82 [9415707.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2070-5 [9605744.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):686-95 [9625737.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):151-6 [9627710.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):155-66 [10064858.001]
  • [Cites] Mutagenesis. 1999 May;14(3):301-15 [10374998.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Dec 1;201(2):178-85 [15541757.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1667-74 [15606143.001]
  • [Cites] Chem Res Toxicol. 2005 Feb;18(2):224-31 [15720126.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1251-8 [15735009.001]
  • [Cites] Crit Rev Toxicol. 2005 Jun;35(5):379-411 [16097136.001]
  • [Cites] Curr Dir Autoimmun. 2006;9:1-17 [16394652.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53 [16467098.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):288-94 [16485905.001]
  • [Cites] Toxicol Lett. 2006 Aug 20;165(2):182-94 [16713138.001]
  • [Cites] BMC Genomics. 2006;7:260 [17042939.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:253-65 [17119207.001]
  • [Cites] Toxicol Sci. 2007 Jan;95(1):63-73 [17060372.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2007;47:263-92 [16970545.001]
  • [Cites] Mutat Res. 2007 Feb 3;615(1-2):87-97 [17141280.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1161-8 [17187366.001]
  • [Cites] Toxicology. 2007 Mar 7;231(2-3):159-74 [17240030.001]
  • [Cites] Chem Res Toxicol. 2007 Mar;20(3):489-96 [17291012.001]
  • [Cites] Cancer Res. 1987 Jul 15;47(14):3701-6 [3109730.001]
  • [Cites] Sci Total Environ. 1987 Oct;66:95-114 [3317821.001]
  • [Cites] Chem Biol Interact. 1988;68(1-2):127-36 [3203403.001]
  • [Cites] Toxicology. 1990 Jan-Feb;60(1-2):127-35 [1690463.001]
  • [Cites] Carcinogenesis. 1990 Sep;11(9):1611-9 [2401051.001]
  • [Cites] Endocrinology. 1991 Aug;129(2):970-82 [1649753.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1939-44 [1934274.001]
  • [Cites] Carcinogenesis. 1992 Jul;13(7):1053-74 [1638670.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):875-8 [8504480.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1753-9 [8179653.001]
  • [Cites] Environ Health Perspect. 1993 Dec;101 Suppl 4:155-65 [7515806.001]
  • [Cites] Mol Carcinog. 1994 Jul;10(3):159-68 [8043197.001]
  • (PMID = 18353537.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / R01 CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825-19; United States / NCI NIH HHS / CA / CA028825-21; United States / NCI NIH HHS / CA / R01 CA028825; United States / NCI NIH HHS / CA / CA028825-19; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA028825-23; United States / NCI NIH HHS / CA / CA028825-22; United States / NCI NIH HHS / CA / CA28825; United States / NCI NIH HHS / CA / CA028825-20; United States / NCI NIH HHS / CA / R01 CA028825-20; United States / NCI NIH HHS / CA / CA028825-24; United States / NCI NIH HHS / CA / R01 CA028825-22; United States / NIEHS NIH HHS / ES / T32 ES007060; United States / NCI NIH HHS / CA / R01 CA028825-24; United States / NIEHS NIH HHS / ES / P30 ES000210; United States / NCI NIH HHS / CA / CA028825-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzopyrenes; 0 / Carcinogens; 0 / DNA Adducts; 0 / Particulate Matter; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Vehicle Emissions; 0 / polycyclic aromatic hydrocarbons-DNA adduct; 191-30-0 / dibenzo(a,l)pyrene; 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp1b1 protein, mouse; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS53855; NLM/ PMC2519885
  •  go-up   go-down


84. Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ: Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg; 2007 May;94(5):627-33
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, its role in the curative treatment of invasive carcinoma is controversial.
  • The median tumour distance from the anal verge was 8 (range 1-16) cm.
  • Histological examination of carcinomas revealed pathological tumour (pT) stage 1 in 31 patients, pT2 in 17 and pT3 in four.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2007 Sep;94(9):1179; author reply 1179 [17701963.001]
  • (PMID = 17335125.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • However, one patient with rectal carcinoma died of lung cancer during the follow-up period.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • The overall and disease-free 5-year survival rates for patients with carcinoma were 96.2% and 88.5%, respectively.
  • With strict patient selection, it is oncologically safe for early-stage rectal carcinomas.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
MedlinePlus Health Information. consumer health - Biopsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma].
  • OBJECTIVE: To analyze the impact of meticulousness of pathologists on the lymph node harvest after radical resection of invasive rectal carcinoma.
  • METHODS: From January 2008 to May 2009, the clinical data of rectal cancer patients undergone operation were reviewed retrospectively.
  • After multidisciplinary cooperation on rectal cancer, a new rule was applied to request the pathologists to find no less than 15 nodes in single colorectal specimen from January 2009.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.
  • The good performance of pathologists could produce adequate number of lymph nodes for rectal cancer without neoadjuvant chemoradiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


87. Yu J, Ohuchida K, Nakata K, Mizumoto K, Cui L, Fujita H, Yamaguchi H, Egami T, Kitada H, Tanaka M: LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer; 2008;7:93
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LIM only 4 is overexpressed in late stage pancreas cancer.
  • BACKGROUND: LIM-only 4 (LMO4), a member of the LIM-only (LMO) subfamily of LIM domain-containing transcription factors, was initially reported to have an oncogenic role in breast cancer.
  • If so, this could result in a better understanding of tumorigenesis in pancreatic cancer.
  • METHODS: We measured LMO4 mRNA levels in cultured cells, pancreatic bulk tissues and microdissected target cells (normal ductal cells; pancreatic intraepithelial neoplasia-1B [PanIN-1B] cells; PanIN-2 cells; invasive ductal carcinoma [IDC] cells; intraductal papillary-mucinous adenoma [IPMA] cells; IPM borderline [IPMB] cells; and invasive and non-invasive IPM carcinoma [IPMC]) by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).
  • RESULTS: 9 of 14 pancreatic cancer cell lines expressed higher levels of LMO4 mRNA than did the human pancreatic ductal epithelial cell line (HPDE).
  • In bulk tissue samples, expression of LMO4 was higher in pancreatic carcinoma than in intraductal papillary-mucinous neoplasm (IPMN) or non-neoplastic pancreas (p < 0.0001 for both).
  • These results suggested that LMO4 is overexpressed at late stages in carcinogenesis of pancreatic cancer.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Analysis of Variance. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Line, Tumor. Humans. LIM Domain Proteins. Neoplasm Staging. Protein-Serine-Threonine Kinases / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 May 19;88(10):1543-8 [12771919.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):93-7 [12629061.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):82-8 [15221649.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71 [2034676.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1887-93 [1923511.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3329-38 [8045262.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):24-31 [7534107.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):263-9 [9665487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11257-62 [9736723.001]
  • [Cites] Biochim Biophys Acta. 1999 Apr 14;1445(1):148-53 [10209267.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] Gene. 2005 Jan 3;344:67-77 [15656974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Rocz Akad Med Bialymst. 2005;50:69-72 [16358942.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343(4):1186-90 [16580634.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3878-82 [16804974.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6431-41 [17452977.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):537-41 [18231110.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1623-31 [11073822.001]
  • [Cites] Mamm Genome. 1999 Nov;10(11):1089-94 [10556429.001]
  • [Cites] Pancreatology. 2008;8(6):587-92 [18849640.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7849-56 [11751867.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1067-72 [12370756.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):125-36 [14505145.001]
  • (PMID = 19099607.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO4 protein, human; 0 / RNA, Messenger; 0 / Transcription Factors; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2628350
  •  go-up   go-down


88. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • CONCLUSION: Our study suggests that SMAD4 gene aberrations are the common event in CRC development but play a differential role in the progression of CRC in higher tumor grade (C+D) and its association with the KRAS mutant status suggest that these two molecules together are responsible for the progression of the tumor to higher/advanced stage.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Mol Cell Biochem. 2009 Dec;332(1-2):51-8 [19513816.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1331-5 [1499084.001]
  • [Cites] Curr Opin Oncol. 1993 Jan;5(1):123-9 [8427884.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):347-9 [8673135.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2578-80 [9205057.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):2033-7 [10208426.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):62-8 [15761872.001]
  • [Cites] Am Surg. 2005 Apr;71(4):336-43 [15943410.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] Int J Biol Sci. 2010;6(1):1-8 [20087440.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Bioessays. 2001 Mar;23(3):223-32 [11223879.001]
  • [Cites] Ann Agric Environ Med. 2001;8(1):1-5 [11426918.001]
  • [Cites] Genome Biol. 2001;2(8):REVIEWS3010 [11532220.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80 [12198585.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):387-93 [14506738.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Exp Oncol. 2004 Jun;26(2):98-105 [15273660.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 [3056609.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Mutat Res. 2009 May 31;676(1-2):5-10 [19486858.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):219-25 [19574674.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Indian J Pathol Microbiol. 1990 Apr;33(2):118-23 [2391141.001]
  • (PMID = 20565773.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2927996
  •  go-up   go-down


89. Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman SM, Dannenberg AJ: Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila); 2009 Nov;2(11):957-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
  • Cyclooxygenase (COX)-derived prostaglandin E(2) (PGE(2)) plays a role in the development and progression of several tumor types including head and neck squamous cell carcinoma (HNSCC).
  • There were no statistically significant differences between patients with (n = 15) or without disease progression (n = 16) with regard to stage, site, treatment received, smoking status, and aspirin use during follow-up.
  • These differences were most evident among patients with early-stage disease.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 1;164(1):361-70 [10605031.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):53-61 [11326316.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2614-9 [11706038.001]
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3395-401 [12067981.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):708-14 [12196922.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6706-11 [12438270.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3425-30 [12960132.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1440-52 [14519750.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):431-6 [14706335.001]
  • [Cites] Anal Biochem. 2004 Nov 15;334(2):266-75 [15494133.001]
  • [Cites] J Am Chem Soc. 1969 Apr 9;91(8):2177-8 [5784182.001]
  • [Cites] Nature. 1970 Feb 14;225(5233):600-4 [4983971.001]
  • [Cites] J Biol Chem. 1971 Nov 25;246(22):6713-21 [5126221.001]
  • [Cites] Prostaglandins. 1976 Feb;11(2):381-97 [772759.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):638-40 [30669.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):658-63 [7295159.001]
  • [Cites] Anal Biochem. 1983 Feb 1;128(2):351-8 [6846812.001]
  • [Cites] Laryngoscope. 1985 Mar;95(3):307-12 [3919231.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(4):308-13 [1577849.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] J Clin Invest. 1994 Feb;93(2):493-8 [8113389.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Feb;54(2):83-94 [8848435.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2254-9 [9151799.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):362-6 [9443418.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1208-16 [9515807.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):664-70 [15695412.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6087-93 [16115954.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6634-40 [16166442.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6976-81 [16172459.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10113-9 [16267038.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3321-8 [16338931.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5338-45 [16707460.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1358-65 [16996805.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):848-55 [18281656.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2158-65 [19276291.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1136-47 [19303855.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):322-9 [19336727.001]
  • (PMID = 19843689.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P01 ES013125; United States / NIDDK NIH HHS / DK / DK48831; United States / NCI NIH HHS / CA / T32 CA09685; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCI NIH HHS / CA / P01 CA106451; United States / NIEHS NIH HHS / ES / ES013125-01A10002; United States / NIGMS NIH HHS / GM / GM15431; United States / NIGMS NIH HHS / GM / P50 GM015431-40; United States / NIDDK NIH HHS / DK / R01 DK048831; United States / NCI NIH HHS / CA / P01 CA77839; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / CA106451-05; United States / NCI NIH HHS / CA / T32 CA009685; United States / NCI NIH HHS / CA / T32 CA009685-18; None / None / / T32 CA009685-18; United States / NIGMS NIH HHS / GM / P01 GM015431; United States / NIGMS NIH HHS / GM / P50 GM015431; United States / NIDDK NIH HHS / DK / R01 DK048831-13; United States / NIEHS NIH HHS / ES / P01 ES013125-01A10002; United States / NIGMS NIH HHS / GM / GM015431-40; United States / NCI NIH HHS / CA / CA077839-100006; United States / NIEHS NIH HHS / ES / ES13125; United States / NCRR NIH HHS / RR / UL1-RR024996; United States / NCRR NIH HHS / RR / UL1 RR024996-03; United States / NCI NIH HHS / CA / P01 CA106451-05; None / None / / UL1 RR024996-03; United States / NIDDK NIH HHS / DK / DK048831-13; United States / NCI NIH HHS / CA / P01 CA077839-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclooxygenase 2 Inhibitors; 0 / Prostaglandins; 73303-30-7 / 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ NIHMS146126; NLM/ PMC2784194
  •  go-up   go-down


90. Koebrugge B, Bosscha K, Ernst MF: Transanal endoscopic microsurgery for local excision of rectal lesions: is there a learning curve? Dig Surg; 2009;26(5):372-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for the local resection of benign and stage T1 rectal lesions in selected patients, associated with lower morbidity and mortality rates than open surgery.
  • All patients undergoing TEM for tubulovillous adenoma or carcinoma between 2002 and 2007 were included.
  • Median distance of the lesion from the anal verge was 7.0 cm; median operating time was 90 min.
  • Postoperative staging revealed 77 tubulovillous adenomas, 22 stage T1, 5 stage T2 and 1 stage T3 carcinomas; tumor resection was radical in 86%.
  • TEM remains the treatment of choice for benign lesions and stage T1 rectal carcinomas in selected patients.
  • [MeSH-major] Adenoma, Villous / surgery. Carcinoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19923824.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Denoya P, Wang H, Sands D, Nogueras J, Weiss E, Wexner SD: Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy. Surg Endosc; 2010 Apr;24(4):933-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The laparoscopic approach for colon cancer has been widely accepted.
  • A few studies have shown that there are advantages of laparoscopic over open TME surgery for rectal cancer.
  • METHODS: All patients with rectal cancer who underwent nCRT were identified; no operations for rectal carcinoma were performed laparoscopically between 1997 and 2005.
  • The procedures performed within each group included 8 abdominoperineal resections and 24 anterior resections, which included 20 colonic J-pouch-anal anastomoses and 4 straight coloanal anastomoses.
  • There were no differences in comorbidities, tumor location, tumor size, tumor stage or radiation dose between the two groups.
  • CONCLUSIONS: In our experience, laparoscopic TME for mid and lower rectal cancer is feasible and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Jan;25(1):328-30 [20552370.001]
  • (PMID = 19851807.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


92. Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J, Capella G, Villanueva A: PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer; 2008 Nov 18;99(10):1718-25
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phosphatase PRL-3 has been involved in different types of cancer, especially in metastases from colorectal carcinoma (CRC).
  • In this study, we explored both isoforms of PRL-3 as a biomarker to predict the recurrence of stage IIIB-C CRC.
  • Besides, our results in a series of 80 stage IIIB-C CRC primary tumours showed that high levels of PRL-3 were an independent predictor of metastasis (P<0.0001; OR: 9.791) in multivariate analysis of a binary logistic regression and that PRL-3 expression tightly correlates with parameters of bad outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):303-10 [17235563.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2448-58 [17570218.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):151-9 [17592549.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):56-64 [18166348.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):381-90 [1986233.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8490-9 [16230676.001]
  • (PMID = 19002188.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC2584959
  •  go-up   go-down


93. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Kishi D, Oda J, Ikematsu H, Mizutani M, Takayanagi S, Tomino Y: Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal. Endoscopy; 2010;42 Suppl 2:E183-4
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrowband imaging colonoscopy with a transparent hood for diagnosis of a squamous cell carcinoma in situ in the anal canal.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640982.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement